Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia
OBJECTIVES:
- Compare the complete response and nodular partial response of patients with relapsed or
refractory chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide
with or without oblimersen.
- Compare the overall response rate, response duration, survival, and time to progression
in patients treated with these regimens.
- Compare the clinical benefit and safety of these regimens in these patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to disease response to prior fludarabine-containing therapy (responsive vs
refractory), number of prior regimens (1-2 vs 3 or more), and duration of response to last
prior therapy (more than 6 months vs 6 months or fewer). Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive oblimersen IV continuously on days 1-7 via an infusion pump
(ending on day 8) and fludarabine IV over 20-30 minutes and cyclophosphamide IV over
30-60 minutes on days 5-7. Patients also receive filgrastim (G-CSF) subcutaneously (SC)
beginning on day 11 and continuing until blood counts recover.
- Arm II: Patients receive fludarabine IV over 20-30 minutes followed by cyclophosphamide
IV over 30-60 minutes on days 1-3. Patients also receive G-CSF SC beginning on day 7
and continuing until blood counts recover.
Treatment in both arms continues every 28 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity.
Patients are followed at 1 month and then every 2 months for 2 years.
PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study
within 1 year.
Interventional
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Stanley R. Frankel, MD
Study Chair
Genta Incorporated
United States: Federal Government
CDR0000068932
NCT00024440
July 2001
Name | Location |
---|---|
Genta Incorporated | Berkeley Heights, New Jersey 07922 |